<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547792</url>
  </required_header>
  <id_info>
    <org_study_id>VXA03-001</org_study_id>
    <nct_id>NCT02547792</nct_id>
  </id_info>
  <brief_title>Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults</brief_title>
  <official_title>Phase 1 , Placebo-Controlled, Dose-Ranging Trial to Determine Safety and Immunogenicity of an Oral Adenoviral-Vector Based Influenza B Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaxart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, single-center, placeb-controlled, double-blind study. The purpose of this
      study is to determine the safety and immunogenicity of an oral vaccine tablet to prevent
      seasonal influenza B tested at two dose levels (low and high dose). The study will enroll 27
      subjects in the low dose cohorts (3 sentinel open label subjects followed by 24 subjects
      (randomized 2:1 to vaccine vs placebo, respectively). Subsequently, 27 subjects will be
      enrolled in the high dose cohort in a similar manner as to the low dose cohort. Safety and
      immunogenicity will be evaluated at Day 28. Long term safety follow-up will be evaluated
      through 1 year post vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll 54 subjects in four cohorts. All subjects will receive a single
      administration of VXA-BYW.10 at a low dose, a high dose or placebo.

      Two sentinel groups will enroll 3 subjects each in an open-label manner (Cohorts 1 and 3) to
      receive VXA-BYW.10 prior to enrolling either of the randomized, controlled cohorts (Cohorts 2
      and 4). Within the double-blinded Cohorts (2 and 4), placebo subjects will receive the same
      number of tablets as the vaccine subjects in that Cohort. Subjects will be enrolled and dosed
      in the low dose groups prior to initiation of dosing in the high dose group.

      Cohort 1: 3 subjects at low dose; Cohort 2: 16 subjects at low dose and 8 placebo; Cohort 3:
      3 subjects at high dose; Cohort 4: 16 subjects at low dose and 8 placebo

      Subjects will be followed for 28 days post vaccination for preliminary immunogenicity.
      Subjects will continue to be followed for 1 year post-vaccination for long term safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2015</start_date>
  <completion_date type="Actual">November 21, 2016</completion_date>
  <primary_completion_date type="Actual">November 21, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Single High Dose of an Oral Influenza B Tablet Vaccine</measure>
    <time_frame>Day 28</time_frame>
    <description>Safety determined by reported solicited (reactogenicity) and unsolicited AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Single high Dose of an Oral Influenza B Tablet Vaccine</measure>
    <time_frame>Day 28</time_frame>
    <description>Efficacy determined by HAI titers at Day 28 post-vaccination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Seasonal Influenza B</condition>
  <arm_group>
    <arm_group_label>VXA-BYW.10 (Low Dose) Oral Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of Influenza B (Low Dose) oral vaccine tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VXA-BYW.10 (High Dose) Oral Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of Influenza B (High Dose) oral vaccine tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo dose (size and number of tablets) to low dose vaccine (part 1) and high dose (part 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VXA-BYW.10 (Low Dose) Oral Vaccine</intervention_name>
    <description>Enteric coated tablet for oral delivery</description>
    <arm_group_label>VXA-BYW.10 (Low Dose) Oral Vaccine</arm_group_label>
    <other_name>Influenza B (Low Dose) Oral Vaccine Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VXA-BYW.10 (High Dose) Oral Vaccine</intervention_name>
    <description>Enteric coated tablet for oral delivery</description>
    <arm_group_label>VXA-BYW.10 (High Dose) Oral Vaccine</arm_group_label>
    <other_name>Influenza B (High Dose) Oral Vaccine Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Tablets</intervention_name>
    <description>Enteric coated tablet for oral delivery</description>
    <arm_group_label>Placebo Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health as established by medical history, physical examination, and laboratory
             testing at the time of enrollment.

        Exclusion Criteria:

          -  Positive for B influenza by HAI.

          -  Has had an influenza vaccine in the past 2 years.

          -  Current history of chronic alcohol use and/or illicit and/or recreational drug use.

          -  History of any confirmed or suspected immunodeficient or immunosuppressive condition

          -  Positive serology for HIV, HCV, or HBV

          -  Previous serious reactions to vaccination such as anaphylaxis, respiratory problems,
             hives, or abdominal pain.

          -  History of irritable bowel disease or other inflammatory digestive or gastrointestinal
             conditions that could affect the intended distribution of the vaccine targeting the
             mucosa of the small intestine

          -  Use of proton pump inhibitors(Nexium, Prilosec).

          -  Stool sample with occult blood at baseline exam

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Liebowitz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vaxart, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCST</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>May 29, 2018</last_update_submitted>
  <last_update_submitted_qc>May 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

